Hypertrophic obstructive cardiomyopathy in liver transplant patients

The optimal treatment strategy for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) and end-stage liver disease (ESLD) is not well defined. Although medical management is the accepted first line treatment, patients who are unresponsive to medication require further interventions. Since ESLD patients have a high operative risk for surgical myomectomy, alcohol septal ablation (ASA) emerges as a good alternative in these cases. The timing of ASA in relation to liver transplantation is still unclear. We report here on the first case of an orthotopic liver transplant-recipient undergoing ASA and the second of a cirrhotic patient requiring ASA as a bridge to liver transplantation. Both patients had a good clinical outcome and we argue that ASA in HOCM patients should be driven by symptom onset, and that in the asymptomatic patient it can be safely deferred until after liver transplantation. (Cardiol J 2008; 15: 74-79

Refractory Thrombocytopenia During Liver Transplantation Requiring Splenectomy

Although thrombocytopenia is common in end-stage liver disease, severe, refractory thrombocytopenia during liver transplantation is rare, and if immune based, usually presents months or years later. This case describes an adult woman in whom preoperative evaluation had not determined an immune-related cause of thrombocytopenia. Clot strength was dramatically impaired as measured by thrombelastography during the transplant. Following a lack of response to repeat platelet transfusions, splenectomy was performed after graft reperfusion with rapid temporal restoration of clot strength. This case shows a severe manifestation of perioperative thrombocytopenia during liver transplantation and clinically guided management when measured clot strength is too low for accurate determination

The Grizzly, October 31, 1980

Campus Poll Favors Reagan, Anderson • Sorority Pleads Guilty To Alcohol Violations • Board Approves Cost Increases For Next Year • Carter & Reagan Make Final Philly Appearances • Athletic Hall of Fame Slated For Founder\u27s Day • It\u27s Laurie for Holmecoming Queen 1980 • Utility Gym Opens With Exciting Concert • Richter Hosts Town Meeting • APO Charter Reviewed • Halloween Dates Back 2000 Years • Booters Drop Three Straight • Gridders Drowned By Swarthmore • Hockey Suffers Season\u27s Second Defeat • Homecoming Sweet For Cross Countryhttps://digitalcommons.ursinus.edu/grizzlynews/1045/thumbnail.jp

The Grizzly, March 27, 1981

Parents Day Slated for Early April • Overwhelming Enthusiasm Welcomes Special Olympics • Bomberger Tower Under Construction • SPC Elects New Grizzly Editor-in-Chief • Shakespeare Opens • Departmental Focus: Math Department • Transplanted Texan: NY to Collegeville • Spectrum Tries New Ticket Sales • Values Next Forum Topic • TV Production in Communications • Language Clubs Host Dessert Festival • Final Exam Schedule • Baseball Team Carries Much Potential • Hoopsters Finish 3rd in Nation • Tennis Team Prepares for Tough Season • Women\u27s Lacrosse Start Season 1-1https://digitalcommons.ursinus.edu/grizzlynews/1056/thumbnail.jp

Liver transplantation for glycogen storage disease types I, III, and IV

Glycogen storage disease (GSD) types I, III, and IV can be associated with severe liver disease. The possible development of hepatocellular carcinoma and/or hepatic failure make these GSDs potential candidates for liver transplantation. Early diagnosis and initiation of effective dietary therapy have dramatically improved the outcome of GSD type I by reducing the incidence of liver adenoma and renal insufficiency. Nine type I and 3 type III patients have received liver transplants because of poor metabolic control, multiple liver adenomas, or progressive liver failure. Metabolic abnormalities were corrected in all GSD type I and type III patients, while catch-up growth was reported only in two patients. Whether liver transplantation results in reversal and/or prevention of renal disease remains unclear. Neutropenia persisted in both GSDIb patients post liver transplantation necessitating continuous granulocyte colony stimulating factor treatment. Thirteen GSD type IV patients were liver transplanted because of progressive liver cirrhosis and failure. All but one patient have not had neuromuscular or cardiac complications during follow-up periods for as long as 13 years. Four have died within a week and 5 years after transplantation. Caution should be taken in selecting GSD type IV candidates for liver transplantation because of the variable phenotype, which may include life-limiting extrahepatic manifestations. It remains to be evaluated, whether a genotype-phenotype correlation exists for GSD type IV, which may aid in the decision making. Conclusion Liver transplantation should be considered for patients with glycogen storage disease who have developed liver malignancy or hepatic failure, and for type IV patients with the classical and progressive hepatic form

The Grizzly, February 13, 1981

Water Crisis Worsens: TCE Also a Problem • Pett Leaving Economics Department • Mobley Breaks Basketball Record • News Briefs: Meistersingers concert in Oreland; Ursinus professor published • Departmental Focus: English Department; History Department • Orientation Committee Applications Being Taken • 1981 Fraternity Pledge Classes • Music News • Female Artists Topic of Forum • Coffeehouse: A Folk Touch • Candidates for USGA Offices • Women\u27s B-Ball Undefeated 9 Straight • Tight Season Ahead for Intramural B-Ball • Badminton Team Playin\u27 Tough • Hoopsters Claim Two More Victims • Grizzly Grapplers Mark at 7-4-1 • Aquabears Dunk Foes: Swimmers Living Up to .500 Goalhttps://digitalcommons.ursinus.edu/grizzlynews/1052/thumbnail.jp

The Grizzly, February 20, 1981

SAC Approves Spring Term 1981 Allocations • SPC to Propose Journalism Seminar • USGA Announces New Officers • Grizzly Planning Satire Issue • Professional Credentials Committee Explored • Departmental Focus: Biology Department • USGA Notes • Astronomy Club Planning Open House • Music News Defends JDB • Lorelei Outcast • Alumni Office Sponsors Homecoming II • Sorority Pledging With Frats • Graterford Visit Provides New Insights • Classics Club Planning Another Trip • Special Olympics Slated for March • Athletic Department Announces Play-off Plans • Sports Profile: Greg Gifford • Basketball Team Clinches MAC Southern Division • Textile Downs Lady Hoopsters • Grapplers: 10-5-1https://digitalcommons.ursinus.edu/grizzlynews/1053/thumbnail.jp

Hypoxia-inducible factor-1α-dependent induction of miR122 enhances hepatic ischemia tolerance

Hepatic ischemia and reperfusion (IR) injury contributes to the morbidity and mortality associated with liver transplantation. microRNAs (miRNAs) constitute a family of noncoding RNAs that regulate gene expression at the posttranslational level through the repression of specific target genes. Here, we hypothesized that miRNAs could be targeted to enhance hepatic ischemia tolerance. A miRNA screen in a murine model of hepatic IR injury pointed us toward the liver-specific miRNA miR122. Subsequent studies in mice with hepatocyte-specific deletion of miR122 (miR122loxP/loxP Alb-Cre+ mice) during hepatic ischemia and reperfusion revealed exacerbated liver injury. Transcriptional studies implicated hypoxia-inducible factor-1α (HIF1α) in the induction of miR122 and identified the oxygen-sensing prolyl hydroxylase domain 1 (PHD1) as a miR122 target. Further studies indicated that HIF1α-dependent induction of miR122 participated in a feed-forward pathway for liver protection via the enhancement of hepatic HIF responses through PHD1 repression. Moreover, pharmacologic studies utilizing nanoparticle-mediated miR122 overexpression demonstrated attenuated liver injury. Finally, proof-of-principle studies in patients undergoing orthotopic liver transplantation showed elevated miR122 levels in conjunction with the repression of PHD1 in post-ischemic liver biopsies. Taken together, the present findings provide molecular insight into the functional role of miR122 in enhancing hepatic ischemia tolerance and suggest the potential utility of pharmacologic interventions targeting miR122 to dampen hepatic injury during liver transplantation

The Grizzly, October 17, 1980

Clouser Organizes Medical Advisory Committee • Union Rules Out Greaseband This Year • Freshman Class Appointments Available • Education Department Optimistic About Jobs • New Profs Appointed In German, History Depts. • Parents\u27 Day Brings Campus Enthusiasm • Staiger Named for State Committee • College Offers Numerous Special Programs • Coffeehouse Of \u27Distant Admiration\u27 • Radio WRUC Making Slow Return • Forum Presents Tyler and Althea • Parents\u27 Day Sees Gym Dedication • SAC Approves Two New Clubs • \u27Gong Show\u27 Provides Friday Night Fun • College Bowl Season Officially Opens • Heathens Take Intramural Title • Booters Kick Del Valley • Women\u27s Volleyball Faces Tough Schedule • Football Finds Season\u27s First W • Hockey Raises Record To 6-1-3https://digitalcommons.ursinus.edu/grizzlynews/1044/thumbnail.jp

The Grizzly, November 7, 1980

Reagan, Anderson Win In Campus Mock Election • Window Replacement To Start Soon • Weekend Crime Continues In New Men\u27s Dormitory • Bookstore Eyes Enlarged Facilities • Honorary Degrees Conferred At Founder\u27s Day • Library To Sponsor Open House • Breakdown For SAC Allocations Explored • Foreign Language Lunches Offered To Students • Another Viewpoint: I Object To War! • Students Do Their Stuff In Talent Show • Springsteen Unveils Interesting New Album • Party Brings Out Spirit On Halloween • Classics Club Underway • Why Carter Lost • UBEC Council Presents Three Faces Of Management • Soccer Finishes Season 7-7-1 • Breaks Carry Ursinus Past Lebanon Valley • Harriers Head Toward MACs • Field Hockey Enters Regional Competitionhttps://digitalcommons.ursinus.edu/grizzlynews/1046/thumbnail.jp